Tolérance de l’association pirfénidone et nintédanib chez des patients atteints de fibrose pulmonaire idiopathique (FPI) : résultats d’une analyse intermédiaire à 12 semaines d’une étude internationale
Sign Up to like & getrecommendations! Published in 2018 at "Revue Des Maladies Respiratoires"
DOI: 10.1016/j.rmr.2017.10.305
Abstract: Introduction La pirfenidone et le nintedanib sont approuves dans le traitement de la FPI, cependant les donnees d’etudes cliniques sur la tolerance de leur utilisation combinee sont limitees. Nous rapportons les resultats d’une analyse intermediaire… read more here.
Keywords: chez; fpi; association; pendant semaines ... See more keywords
Integrated bioinformatics analysis identifies established and novel TGFβ1-regulated genes modulated by anti-fibrotic drugs
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-07151-1
Abstract: Fibrosis is a leading cause of morbidity and mortality worldwide. Although fibrosis may involve different organ systems, transforming growth factor-β (TGFβ) has been established as a master regulator of fibrosis across organs. Pirfenidone and Nintedanib… read more here.
Keywords: novel tgf; anti fibrotic; analysis; tgf ... See more keywords
Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?)
Sign Up to like & getrecommendations! Published in 2017 at "Current Opinion in Pulmonary Medicine"
DOI: 10.1097/mcp.0000000000000408
Abstract: Purpose of review Therapeutic advances in the management of idiopathic pulmonary fibrosis (IPF) has led to improved outcomes with the use of the antifibrotic agents pirfenidone and nintedanib, with a number of randomized studies demonstrating… read more here.
Keywords: treatment; antifibrotic drugs; pulmonary fibrosis; ipf ... See more keywords
M21 Patient stories: the use of novel anti-fibrotics, pirfenidone and nintedanib, in the management of idiopathic pulmonary fibrosis, ipf
Sign Up to like & getrecommendations! Published in 2017 at "Thorax"
DOI: 10.1136/thoraxjnl-2017-210983.443
Abstract: Background Pirfenidone and Nintedanib have been approved by NICE with the aim of attenuating progression and extending the prognosis for patients with IPF. There are no indications as to which should be used first line.… read more here.
Keywords: pirfenidone; treatment; management; pirfenidone nintedanib ... See more keywords
Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study
Sign Up to like & getrecommendations! Published in 2020 at "BMC Pulmonary Medicine"
DOI: 10.1186/s12890-020-01224-5
Abstract: Background Pirfenidone and nintedanib are antifibrotic therapies which slow disease progression in idiopathic pulmonary fibrosis (IPF), an irreversible, progressive lung disease with poor prognosis. We compared adherence, persistence, and healthcare costs between patients initiating one… read more here.
Keywords: idiopathic pulmonary; cohort; healthcare costs; pulmonary fibrosis ... See more keywords
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Molecular Biosciences"
DOI: 10.3389/fmolb.2020.581828
Abstract: Background Pirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease. Here, we describe our… read more here.
Keywords: idiopathic pulmonary; pulmonary fibrosis; treated pirfenidone; pirfenidone ... See more keywords